Drug intelligence / Profile preview

atomoxetine + olanzapine

Development stage: Preclinical
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy of atomoxetine (a selective norepinephrine reuptake inhibitor) and olanzapine (an atypical antipsychotic). This combination has been studied for treating attention-deficit/hyperactivity disorder (ADHD) with comorbid disruptive behaviors in children and adolescents. Clinical studies have shown statistically significant improvement in ADHD symptoms and overt aggression with this combination, though olanzapine is associated with significant weight gain.

Targets

HTR2A (Serotonin receptor 5-HT2A)NET (Norepinephrine Transporter)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on atomoxetine + olanzapine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atomoxetine + olanzapine.

Explore the full profile